Substantial disease heterogeneity, extensive corticosteroid reliance, and steep increases in healthcare costs with treatment escalation were observed, underscoring an urgent need for CHE-specific therapies capable of providing durable control and reducing inappropriate resource use.
Armstrong et al. (Fri,) studied this question.